Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health’s rise from start-up to public telehealth leader is powered by one metric investors can’t ignore: subscriber retention across dermatology, mental-health and primary-care lines. That data lives deep inside each SEC filing.
Stock Titan surfaces exactly what matters. Our AI engine turns the dense language of a Hims & Hers Health annual report 10-K simplified into plain-English insights on fulfillment margins, privacy compliance costs and segment revenue. Need the latest Hims & Hers Health quarterly earnings report 10-Q filing? It arrives here in real time, alongside concise commentary that links prescription growth to cash-flow swings. Material developments—regulatory shifts, pharmacy partnerships, class-action updates—trigger a Hims & Hers Health 8-K material events explained snapshot within minutes.
Want to monitor management moves? Our alerts flag every Hims & Hers Health Form 4 insider transactions real-time so you can compare option exercises against marketing-spend disclosures. The page also answers common searches such as “Hims & Hers Health insider trading Form 4 transactions” and “Hims & Hers Health proxy statement executive compensation,” pairing raw documents with readable summaries.
- AI-powered digests that make understanding Hims & Hers Health SEC documents with AI straightforward
- Cross-links to Hims & Hers Health earnings report filing analysis for trend tracking
- Downloadable exhibits covering Hims & Hers Health executive stock transactions Form 4
Stop wading through 300 pages; let Stock Titan transform complex disclosures into investable clarity.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported transactions on 08/13/2025. The filing shows acquisition of 11,581 shares at an exercise price of $5.01 and a contemporaneous sale of 11,581 shares at a weighted average price of $48.0459, with sales executed in the range $47.84–$48.32. The report also records a transfer of 62,722 Class A shares from the Oluyemi Okupe Separate Property Trust dated 9-1-2021 to the reporting person’s direct holdings. Post-transaction direct beneficial ownership is reported as 65,665 Class A shares. The exercised options referenced vest per a schedule beginning January 24, 2023, with full monthly vesting thereafter and expire February 23, 2032.
Andrew Dudum, Chief Executive Officer and director of Hims & Hers Health, Inc., reports beneficial ownership equal to 23,820,905 shares of Class A common stock on a fully converted/exercised basis, representing 10.3% of Class A. That total combines shares held directly and in affiliated trusts, Class V common stock that converts into Class A, restricted stock units expected to settle within 60 days, and a large block of stock options exercisable within 60 days.
The filing breaks down the holdings: 9,333,039 Class A shares held by affiliated trusts, 92,313 held directly, 8,377,623 Class V shares, 164,368 Class A shares underlying RSUs expected to settle within 60 days, 5,643,186 options exercisable within 60 days, plus additional options and RSUs subject to vesting; 1,296,568 RSUs not expected to settle within 60 days are excluded from the aggregate amount. The filing also notes that Class V shares convert into Class A upon transfer or by Board resolution after specified trigger conditions.
Capital World Investors (a division of Capital Research and Management Company and affiliated investment management entities) is reported as the beneficial owner of 18,559,302 shares of Hims & Hers Health, Inc., representing 8.6% of the approximately 215.5 million shares outstanding. CWI holds 18,553,317 shares with sole voting power and 18,559,302 shares with sole dispositive power; no shared voting or dispositive power is reported. The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control. The Growth Fund of America is identified in the filing as an account on behalf of which ownership is reported.
Hims & Hers Health insider Melissa Baird filed a Form 144 notifying a proposed sale of 33,333 Class A common shares through Goldman Sachs & Co. LLC, with an aggregate market value of $1,598,650.68. The filing states the shares were acquired on 05/13/2020 as compensation via stock options and that the planned payment method is a cashless exercise/same-day sale. The document lists 217,641,958 shares outstanding for the class and discloses multiple individual sales by Ms. Baird during May–July 2025 with specific dates, share amounts and gross proceeds. No earnings, guidance or other corporate actions are included in this filing.
Hims & Hers Health insider Boughton Soleil, the company's Chief Legal Officer, reported a sale of 2,572 shares of Class A common stock on 08/11/2025 at a reported price of $51.64 per share, leaving 153,021 shares beneficially owned. The filing is a Section 16 Form 4 disclosing this change in beneficial ownership.
Andrew Dudum, identified as Chief Executive Officer, director and a 10% owner of Hims & Hers Health, Inc. (HIMS), reported a sale of Class A common stock on 08/07/2025. The Form 4 shows a disposition of 660,000 shares reported as a sale (code S) at an average weighted price of $50.582 per share.
The filing itemizes the reporting person’s remaining beneficial holdings held indirectly through multiple trusts. The form shows 2,214,769 shares noted alongside the Dudum Family Heritage Trust, and additional indirect trust holdings listed as 1,194,545, 990,410, 1,286,627, 534,491, 186,723, 190,126, 321,657, 1,584,506 and 829,185 shares. The Form 4 was signed by an attorney-in-fact.
Form 144 notice: The filing reports a proposed sale of 2,572 Class A shares of Hims & Hers Health, Inc. through Fidelity Brokerage Services LLC on 08/11/2025, with an aggregate market value of $132,818.08. The company has 217,641,958 shares outstanding. The 2,572 shares were acquired on 06/15/2025 through restricted stock vesting from the issuer and were recorded as compensation.
The filing also lists recent sales by Soleil Boughton over the prior three months: seven transactions between 05/12/2025 and 07/28/2025 totaling 22,207 shares for aggregate gross proceeds of $1,228,936.95. The form includes the standard insider representation regarding material nonpublic information.
Hims & Hers Health director David B. Wells was granted 3,656 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Class A common stock. The award is recorded with a $0 per‑unit price and is reported as direct beneficial ownership. The RSUs vest upon continuous service on the earlier of the company’s 2026 annual meeting or June 15, 2026, and the transaction date on the form is 08/06/2025. The filing documents a routine equity grant to a director with vesting tied to continued service.
Christopher D. Payne, a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A common stock, and the reported beneficial ownership following the grant is 3,656 shares held directly.
The RSUs vest upon the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, and are subject to continuous service. The award carries no exercise price and converts one-for-one into Class A common stock when vested, increasing the director’s direct equity stake but remaining subject to standard service and vesting conditions.
Andrea Perez Garcia, identified as a Director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) with an indicated price of $0 on 08/06/2025. The Form 4 reports the award as a derivative security and shows 3,656 shares beneficially owned following the transaction, held in a direct ownership form.
The filing explains each RSU is a contingent right to receive one share of Class A Common Stock and that the RSUs will vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026, subject to continuous service. The Form 4 was signed by an attorney-in-fact on 08/08/2025.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
